DK1992635T3 - Oligonukleotider med immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse - Google Patents

Oligonukleotider med immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse

Info

Publication number: DK1992635T3
Authority: DK; Denmark
Prior art keywords: methods; sequence oligonucleotides; immunostimulatory sequence; immunostimulatory; oligonucleotides
Prior art date: 2002-12-23

Application number

DK08013086.7T

Other languages

English (en)

Inventor

Dino Dina

Karen L Fearon

Jason Marshall

Original Assignee

Dynavax Tech Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-23

Filing date

2003-12-18

Publication date

2012-03-05

2003-12-18 Application filed by Dynavax Tech Corp filed Critical Dynavax Tech Corp

2012-03-05 Application granted granted Critical

2012-03-05 Publication of DK1992635T3 publication Critical patent/DK1992635T3/da

Links

108091034117 Oligonucleotide Proteins 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
230000003308 immunostimulating effect Effects 0.000 title 1
230000002519 immonomodulatory effect Effects 0.000 abstract 3
102000040430 polynucleotide Human genes 0.000 abstract 2
108091033319 polynucleotide Proteins 0.000 abstract 2
239000002157 polynucleotide Substances 0.000 abstract 2

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
- A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/333—Modified A
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/336—Modified G
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Pulmonology (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Microbiology (AREA)
Dermatology (AREA)
Physics & Mathematics (AREA)
Toxicology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
Ophthalmology & Optometry (AREA)
Otolaryngology (AREA)
Agronomy & Crop Science (AREA)
Pest Control & Pesticides (AREA)
Dentistry (AREA)
Environmental Sciences (AREA)

DK08013086.7T 2002-12-23 2003-12-18 Oligonukleotider med immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse DK1992635T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US43612202P	2002-12-23	2002-12-23
US44788503P	2003-02-13	2003-02-13
US46754603P	2003-05-01	2003-05-01
EP03814325A EP1575977B1 (en)	2002-12-23	2003-12-18	Immunostimulatory sequence oligonucleotides and methods of using the same

Publications (1)

Publication Number	Publication Date
DK1992635T3 true DK1992635T3 (da)	2012-03-05

Family

ID=32686090

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK03814325T DK1575977T3 (da)	2002-12-23	2003-12-18	Oligonukleotider med Immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse
DK08013086.7T DK1992635T3 (da)	2002-12-23	2003-12-18	Oligonukleotider med immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK03814325T DK1575977T3 (da)	2002-12-23	2003-12-18	Oligonukleotider med Immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse

Country Status (17)

Country	Link
US (1)	US7745606B2 (da)
EP (2)	EP1992635B1 (da)
JP (2)	JP5102959B2 (da)
KR (3)	KR20120128729A (da)
CN (2)	CN100546998C (da)
AT (2)	ATE544772T1 (da)
AU (1)	AU2003297483B2 (da)
CA (1)	CA2511475C (da)
CY (2)	CY1109642T1 (da)
DE (1)	DE60329223D1 (da)
DK (2)	DK1575977T3 (da)
ES (2)	ES2328807T3 (da)
NZ (1)	NZ541027A (da)
PT (2)	PT1992635E (da)
SG (2)	SG2011035342A (da)
SI (1)	SI1575977T1 (da)
WO (1)	WO2004058179A2 (da)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030129251A1 (en) *	2000-03-10	2003-07-10	Gary Van Nest	Biodegradable immunomodulatory formulations and methods for use thereof
KR100917101B1 (ko) *	2000-08-04	2009-09-15	도요 보세키 가부시키가이샤	플렉시블 금속적층체 및 그 제조방법
EP1404873B1 (en) *	2001-06-21	2013-05-22	Dynavax Technologies Corporation	Chimeric immunomodulatory compounds and methods of using the same
ES2314099T3 (es) *	2001-08-17	2009-03-16	Coley Pharmaceutical Gmbh	Oligonucleotidos inmunoestimulantes con motivos combinados con actividad mejorada.
EP1551376A4 (en) *	2002-08-12	2010-10-06	Dynavax Tech Corp	IMMUNOMODULATORY COMPOSITIONS, PREPARATION METHOD AND USER METHOD THEREFOR
JP2006512927A (ja) *	2002-12-11	2006-04-20	コーリーファーマシューティカルグループ，インコーポレイテッド	５’ｃｐｇ核酸およびその使用方法
US8158768B2 (en)	2002-12-23	2012-04-17	Dynavax Technologies Corporation	Immunostimulatory sequence oligonucleotides and methods of using the same
ATE544772T1 (de)	2002-12-23	2012-02-15	Dynavax Tech Corp	Immunstimulierende sequenz-oligonukleotide und verwendungsverfahren dafür
PL1794174T3 (pl) *	2004-09-01	2012-11-30	Dynavax Tech Corp	Sposoby i kompozycje do hamowania wrodzonych odpowiedzi immunologicznych i autoodporności
US8072945B2 (en)	2004-09-24	2011-12-06	Aes Corporation	Link layered networks
JP2008000001A (ja) *	2004-09-30	2008-01-10	Osaka Univ	免疫刺激オリゴヌクレオチドおよびその医薬用途
MY159370A (en) *	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
WO2006080596A1 (en) *	2005-01-28	2006-08-03	Hyung-Joo Kwon	Oligonucleotides derived from mycobacterium for stimulating immune function, treating immune-related diseases, atopic dermatitis and/or protecting normal immune cell
SG160336A1 (en)	2005-03-04	2010-04-29	Dynavax Tech Corp	Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
EP1874325A2 (en) *	2005-04-08	2008-01-09	Coley Pharmaceutical Group, Inc.	Methods for treating infectious disease exacerbated asthma
EP1904077B1 (en)	2005-07-01	2009-08-12	Index Pharmaceuticals AB	Modulating responsiveness to steroids
DK2380584T3 (da)	2005-07-01	2014-01-20	Index Pharmaceuticals Ab	Immunstimulerende fremgangsmåde
CA2523032A1 (en)	2005-10-07	2007-04-07	Immunovaccine Technologies Inc.	Vaccines for cancer therapy
WO2007050034A1 (en)	2005-10-28	2007-05-03	Index Pharmaceuticals Ab	Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
EP2005161B1 (en) *	2006-03-17	2016-02-24	NewSouth Innovations Pty Limited	Electrochemical sensor
AU2007268534B2 (en)	2006-05-31	2011-07-14	Osaka University	Immunostimulatory oligonucleotide and pharmaceutical application thereof
CA2669137A1 (en)	2006-11-09	2008-06-19	Dynavax Technologies Corporation	Long term disease modification using immunostimulatory oligonucleotides
ES2539353T3 (es) *	2007-08-01	2015-06-30	Idera Pharmaceuticals, Inc.	Nuevos agonistas sintéticos de TLR9
CA2697049A1 (en) *	2007-08-21	2009-02-26	Dynavax Technologies Corporation	Composition and methods of making and using influenza proteins
JP5731198B2 (ja)	2007-09-27	2015-06-10	イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅＴｅｃｈｎｏｌｏｇｉｅｓＩｎｃ．	インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用
WO2009055076A2 (en)	2007-10-26	2009-04-30	Dynavax Technologies Corporation	Methods and compositions for inhibition of immune responses and autoimmunity
US8815817B2 (en)	2008-05-15	2014-08-26	Dynavax Technologies Corporation	Long term disease modification using immunostimulatory oligonucleotides
CN102056622B (zh)	2008-06-05	2016-04-06	免疫疫苗技术有限公司	包含脂质体、抗原、多核苷酸和含疏水物质的连续相的载体的组合物
AU2010226466A1 (en) *	2009-03-20	2011-10-20	Alios Biopharma, Inc.	Substituted nucleoside and nucleotide analogs
US8981044B2 (en)	2010-04-21	2015-03-17	National University Corporation Hokkaido University	Lipid membrane structure having intranuclear migrating property
CN102905728B (zh)	2010-05-26	2015-11-25	西莱克塔生物科技公司	具有不偶合的佐剂的纳米载体组合物
MX338980B (es)	2010-06-16	2016-05-06	Dynavax Tech Corp	Metodos de tratamiento utilizando inhibidores de tlr7 y/o tlr9.
GEP20156313B (en)	2010-09-22	2015-07-10	Alios Biopharma Inc	Substituted nucleotide analogs
EP2640190A4 (en)	2010-11-05	2016-05-11	Selecta Biosciences Inc	MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
WO2012068295A1 (en) *	2010-11-16	2012-05-24	Selecta Biosciences, Inc.	Immunostimulatory oligonucleotides
EP2471926A3 (en) *	2010-12-30	2012-07-11	Intervet International BV	Immunostimulatory oligodeoxynucleotides
US9446120B2 (en) *	2011-04-15	2016-09-20	Osaka University	DNA vaccine
EP2714907B1 (en) *	2011-05-26	2016-06-15	Intervet International B.V.	Immunostimulatory oligodeoxynucleotides
CA2834440A1 (en) *	2011-05-26	2012-11-29	Intervet International B.V.	Immunostimulatory oligodeoxynucleotides
US20130028857A1 (en)	2011-07-29	2013-01-31	Selecta Biosciences, Inc.	Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
CN113876945A (zh)	2011-10-06	2022-01-04	免疫疫苗技术有限公司	包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
US8980865B2 (en)	2011-12-22	2015-03-17	Alios Biopharma, Inc.	Substituted nucleotide analogs
US8916538B2 (en)	2012-03-21	2014-12-23	Vertex Pharmaceuticals Incorporated	Solid forms of a thiophosphoramidate nucleotide prodrug
EP2827876A4 (en)	2012-03-22	2015-10-28	Alios Biopharma Inc	PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
CN102719436A (zh) *	2012-06-27	2012-10-10	南开大学	一种寡核苷酸及其制备在防治心肌肥大与心力衰竭药物中的用途
JP6001974B2 (ja)	2012-09-21	2016-10-05	アンジェスＭｇ株式会社	アポリポプロテイン（ａ）の特異的エピトープを含むＤＮＡワクチン
EP3164113B1 (en)	2014-06-04	2019-03-27	Exicure, Inc.	Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US11213593B2 (en)	2014-11-21	2022-01-04	Northwestern University	Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
EP3238727B1 (en) *	2014-12-25	2023-01-18	National Institutes of Biomedical Innovation, Health and Nutrition	Non-aggregating immunostimulatory oligonucleotides
EP3892284B1 (en) *	2015-05-29	2024-05-22	Merck Sharp & Dohme LLC	Combination of a pd-1 antagonist and a cpg-c type oligonucleotide for treating cancer
WO2016196178A1 (en) *	2015-05-29	2016-12-08	Merck Sharp & Dohme Corp.	Combination of an anti-il-10 antibody and a cpg-c type oligonucleotide for treating cancer
AU2016270782B2 (en) *	2015-05-29	2021-08-12	Dynavax Technologies Corporation	Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lung
CN106256905B (zh) *	2015-11-24	2019-08-13	华中农业大学	一种对草鱼有免疫增强活性的CpG ODN序列及其应用
CN105567782B (zh) *	2016-01-29	2020-08-04	山东省农业科学院畜牧兽医研究所	鸡胚成纤维细胞在体外筛选CpG寡聚脱氧核苷酸活性分子中的应用
CN109475612A (zh) *	2016-04-15	2019-03-15	戴纳瓦克斯技术公司	肿瘤内给予含有Toll样受体9激动剂和肿瘤抗原的颗粒用于治疗癌症
US11364304B2 (en)	2016-08-25	2022-06-21	Northwestern University	Crosslinked micellar spherical nucleic acids
IL292658A (en) *	2016-09-15	2022-07-01	Idera Pharmaceuticals Inc	Immune modulation with tlr9 agonists for cancer treatment
WO2018209270A1 (en)	2017-05-11	2018-11-15	Northwestern University	Adoptive cell therapy using spherical nucleic acids (snas)
GB201718701D0 (en) *	2017-11-13	2017-12-27	Syngenta Participations Ag	Improvements in or relating to gene silencing
WO2019200238A1 (en)	2018-04-14	2019-10-17	Dynavax Technologies Corporation	Combinations including a cpg-c type oligonucleotide and a histone deacetylase inhibitor for treating cancer
WO2020081398A1 (en)	2018-10-14	2020-04-23	Dynavax Technologies Corporation	Combination including a cpg-c type oligonucleotide and a pd-1 antagonist for treating breast cancer
WO2020228606A1 (en) *	2019-05-10	2020-11-19	Microbio (Shanghai) Co., Ltd.	Dimeric cpg oligonucleotides for use in modulating immune responses
CN113058033B (zh) *	2019-12-16	2024-07-09	远大赛威信生命科学(南京)有限公司	一种用于预防和治疗乙型肝炎的药物组合物及其用途
TWI833056B (zh)	2019-12-31	2024-02-21	財團法人工業技術研究院	核酸藥物複合體以及其用途
WO2021178306A1 (en) *	2020-03-01	2021-09-10	Dynavax Technologies Corporation	Coronavirus vaccines comprising a tlr9 agonist
AU2021230501A1 (en) *	2020-03-01	2022-10-27	Dynavax Technologies Corporation	Coronavirus vaccines comprising a TLR9 agonist
US20230092650A1 (en) *	2020-03-01	2023-03-23	Dynavax Technologies Corporation	Coronavirus vaccines comprising a tlr9 agonist
WO2023081486A1 (en)	2021-11-08	2023-05-11	Nurix Therapeutics, Inc.	Toll-like receptor therapy combinations with cbl-b inhibitor compounds
EP4713019A2 (en) *	2023-05-16	2026-03-25	The Board of Trustees of the Leland Stanford Junior University	Cpg conjugates and methods of use
WO2025031498A1 (zh) *	2023-08-10	2025-02-13	浙江海昶生物医药技术有限公司	Toll样受体激动剂及其应用

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4458066A (en)	1980-02-29	1984-07-03	University Patents, Inc.	Process for preparing polynucleotides
US4948882A (en)	1983-02-22	1990-08-14	Syngene, Inc.	Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4650675A (en)	1983-08-18	1987-03-17	The Children's Medical Center Corporation	Oligonucleotide conjugates
US5118802A (en)	1983-12-20	1992-06-02	California Institute Of Technology	DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US5118800A (en)	1983-12-20	1992-06-02	California Institute Of Technology	Oligonucleotides possessing a primary amino group in the terminal nucleotide
US4849513A (en)	1983-12-20	1989-07-18	California Institute Of Technology	Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
US5015733A (en)	1983-12-20	1991-05-14	California Institute Of Technology	Nucleosides possessing blocked aliphatic amino groups
US4828991A (en)	1984-01-31	1989-05-09	Akzo N.V.	Tumor specific monoclonal antibodies
US4910300A (en)	1985-12-11	1990-03-20	Chiron Corporation	Method for making nucleic acid probes
US5093232A (en)	1985-12-11	1992-03-03	Chiron Corporation	Nucleic acid probes
US5124246A (en)	1987-10-15	1992-06-23	Chiron Corporation	Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5278302A (en)	1988-05-26	1994-01-11	University Patents, Inc.	Polynucleotide phosphorodithioates
US5391723A (en)	1989-05-31	1995-02-21	Neorx Corporation	Oligonucleotide conjugates
US5552391A (en)	1990-01-16	1996-09-03	La Jolla Pharmaceutical Company	Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5460831A (en)	1990-06-22	1995-10-24	The Regents Of The University Of California	Targeted transfection nanoparticles
JPH04352724A (ja) *	1990-07-27	1992-12-07	Mitsui Toatsu Chem Inc	免疫調節型治療剤
EP0468520A3 (en)	1990-07-27	1992-07-01	Mitsui Toatsu Chemicals, Inc.	Immunostimulatory remedies containing palindromic dna sequences
US5932214A (en) *	1994-08-11	1999-08-03	Biogen, Inc.	Treatment for inflammatory bowel disease with VLA-4 blockers
US5849719A (en) *	1993-08-26	1998-12-15	The Regents Of The University Of California	Method for treating allergic lung disease
WO1995026204A1 (en) *	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6239116B1 (en) *	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
WO1996002555A1 (en)	1994-07-15	1996-02-01	The University Of Iowa Research Foundation	Immunomodulatory oligonucleotides
US6429199B1 (en)	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
CA2244946C (en)	1996-01-30	2010-04-13	The Regents Of The University Of California	Gene expression vectors which generate an antigen specific immune response and methods of using the same
DE19631919C2 (de)	1996-08-07	1998-07-16	Deutsches Krebsforsch	Anti-Sinn-RNA mit Sekundärstruktur
JP4111403B2 (ja) *	1996-10-11	2008-07-02	ザリージェンツオブザユニバーシティーオブカリフォルニア	免疫刺激ポリヌクレオチド／免疫調節分子複合体
WO1998037919A1 (en)	1997-02-28	1998-09-03	University Of Iowa Research Foundation	USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
AU753688B2 (en)	1997-03-10	2002-10-24	Ottawa Civic Loeb Research Institute	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6406705B1 (en) *	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) *	1997-04-30	2002-07-30	Hybridon, Inc.	Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
JP2001526688A (ja)	1997-05-19	2001-12-18	メルクエンドカンパニーインコーポレーテッド	オリゴヌクレオチドアジュバント
AU7690898A (en)	1997-05-20	1998-12-11	Ottawa Civic Hospital Loeb Research Institute	Vectors and methods for immunization or therapeutic protocols
US6589940B1 (en) *	1997-06-06	2003-07-08	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO1998055495A2 (en)	1997-06-06	1998-12-10	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US20040006034A1 (en) *	1998-06-05	2004-01-08	Eyal Raz	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6157654A (en) *	1997-06-24	2000-12-05	Alcatel Networks Corporation	Adaptive service weight assignments for ATM scheduling
DK1009413T3 (da)	1997-09-05	2007-06-11	Univ California	Anvendelse af immunstimulerende oligonukleotider til forebyggelse eller behandling af astma
GB9727262D0 (en)	1997-12-24	1998-02-25	Smithkline Beecham Biolog	Vaccine
JPH11209289A (ja) *	1998-01-22	1999-08-03	Taisho Pharmaceut Co Ltd	粘膜免疫誘起剤
US6218371B1 (en)	1998-04-03	2001-04-17	University Of Iowa Research Foundation	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
CA2328602A1 (en)	1998-05-06	1999-11-11	University Of Iowa Research Foundation	Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
DK1733735T3 (da)	1998-05-22	2017-06-19	Ottawa Hospital Res Inst	Fremgangsmåder og produkter til induktion af mukosal immunitet
US6562798B1 (en)	1998-06-05	2003-05-13	Dynavax Technologies Corp.	Immunostimulatory oligonucleotides with modified bases and methods of use thereof
WO2000006588A1 (en)	1998-07-27	2000-02-10	University Of Iowa Research Foundation	STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS
ES2394458T3 (es) *	1998-09-09	2013-01-31	Genzyme Corporation	Metilación de vectores plasmídicos
US20020065236A1 (en) *	1998-09-09	2002-05-30	Yew Nelson S.	CpG reduced plasmids and viral vectors
AU766492B2 (en)	1998-09-18	2003-10-16	Dynavax Technologies Corporation	Methods of treating IgE-associated disorders and compositions for use therein
WO2000021556A1 (en)	1998-10-09	2000-04-20	Dynavax Technologies Corporation	Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
US6424622B1 (en) *	1999-02-12	2002-07-23	Nec Usa, Inc.	Optimal buffer management scheme with dynamic queue length thresholds for ATM switches
US6647011B1 (en) *	1999-02-22	2003-11-11	Marconi Communications, Inc.	Method and system for switching using an arbitrator
US6628668B1 (en) *	1999-03-16	2003-09-30	Fujitsu Network Communications, Inc.	Crosspoint switch bandwidth allocation management
WO2000054803A2 (en)	1999-03-16	2000-09-21	Panacea Pharmaceuticals, Llc	Immunostimulatory nucleic acids and antigens
AU4343700A (en)	1999-04-12	2000-11-14	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Oligodeoxynucleotide and its use to induce an immune response
ATE275727T1 (de)	1999-04-29	2004-09-15	Coley Pharm Gmbh	Screening nach modulatoren der funktion von immunstimulatorischer dna
AU4992900A (en)	1999-05-06	2000-11-21	Immune Response Corporation, The	Hiv immunogenic compositions and methods
EP2314693A3 (en) *	1999-08-13	2012-11-28	Idera Pharmaceuticals, Inc.	Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7479285B1 (en) *	1999-08-19	2009-01-20	Dynavax Technologies Corporation	Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
CN100368020C (zh)	1999-08-27	2008-02-13	不列颠哥伦比亚大学	用于刺激细胞因子分泌和诱导免疫应答的组合物
US6165726A (en) *	1999-09-21	2000-12-26	Ut-Battelle, Llc	Non-radioactive methods for chemical cleavage sequencing and footprinting of nucleic acids
IL148843A0 (en) *	1999-09-25	2002-09-12	Univ Iowa Res Found	Immunostimulatory nucleic acids
NZ517928A (en)	1999-09-27	2004-09-24	Coley Pharm Gmbh	Methods related to immunostimulatory nucleic acid-induced interferon
US7223398B1 (en)	1999-11-15	2007-05-29	Dynavax Technologies Corporation	Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
AU2593701A (en)	1999-12-21	2001-07-03	Regents Of The University Of California, The	Method for preventing an anaphylactic reaction
EP1322655B1 (en)	2000-01-14	2007-11-14	The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services	Oligodeoxynucleotide and its use to induce an immune response
EP1252307B1 (en)	2000-01-26	2008-01-02	Idera Pharmaceuticals, Inc.	MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
AT409085B (de)	2000-01-28	2002-05-27	Cistem Biotechnologies Gmbh	Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
WO2001055341A2 (en)	2000-01-31	2001-08-02	The Regents Of The University Of California	Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
WO2001062207A2 (en)	2000-02-23	2001-08-30	The Regents Of The University Of California	Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US20020098199A1 (en)	2000-03-10	2002-07-25	Gary Van Nest	Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US20020107212A1 (en)	2000-03-10	2002-08-08	Nest Gary Van	Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US20030129251A1 (en) *	2000-03-10	2003-07-10	Gary Van Nest	Biodegradable immunomodulatory formulations and methods for use thereof
US20020028784A1 (en)	2000-03-10	2002-03-07	Nest Gary Van	Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
US20010046967A1 (en)	2000-03-10	2001-11-29	Gary Van Nest	Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US7129222B2 (en) *	2000-03-10	2006-10-31	Dynavax Technologies Corporation	Immunomodulatory formulations and methods for use thereof
US7157437B2 (en)	2000-03-10	2007-01-02	Dynavax Technologies Corporation	Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
WO2001072123A1 (en)	2000-03-28	2001-10-04	The Regents Of The University Of California	Methods for increasing a cytotoxic t lymphocyte response in vivo
US20020142978A1 (en)	2000-04-07	2002-10-03	Eyal Raz	Synergistic improvements to polynucleotide vaccines
JP2003531915A (ja) *	2000-05-01	2003-10-28	ハイブリドン・インコーポレイテッド	ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ誘導性免疫刺激の調節
EP1292331A2 (en)	2000-06-07	2003-03-19	Biosynexus Incorporated	Immunostimulatory rna/dna hybrid molecules
JP2005512499A (ja) *	2000-09-01	2005-05-12	エピゲノミクスアーゲー	進行中の疾病または特定の疾病の発病素質の診断
ATE384072T1 (de)	2000-09-26	2008-02-15	Idera Pharmaceuticals Inc	Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen
KR100343935B1 (ko) *	2000-10-09	2002-07-20	주식회사 하이닉스반도체	Ｉｍｔ-2000 시스템내 ａｔｍ 교환기에서의 ｄｂｗｒｒ 셀스케줄링 장치 및 방법
ES2307568T3 (es)	2000-12-08	2008-12-01	Coley Pharmaceutical Gmbh	Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
US6882625B2 (en) *	2000-12-14	2005-04-19	Nokia Networks Oy	Method for scheduling packetized data traffic
NZ526322A (en) *	2000-12-27	2005-06-24	Dynavax Tech Corp	Immunomodulatory polynucleotides and methods of using the same
WO2002074922A2 (en)	2001-03-16	2002-09-26	The Regents Of The University Of California	Compositions and methods for modulating an immune response
US7176296B2 (en) *	2001-04-30	2007-02-13	Idera Pharmaceuticals, Inc.	Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7105495B2 (en) *	2001-04-30	2006-09-12	Idera Pharmaceuticals, Inc.	Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7785610B2 (en) *	2001-06-21	2010-08-31	Dynavax Technologies Corporation	Chimeric immunomodulatory compounds and methods of using the same—III
US20040132677A1 (en) *	2001-06-21	2004-07-08	Fearon Karen L.	Chimeric immunomodulatory compounds and methods of using the same-IV
EP1404873B1 (en) *	2001-06-21	2013-05-22	Dynavax Technologies Corporation	Chimeric immunomodulatory compounds and methods of using the same
CA2456328C (en) *	2001-08-07	2015-05-26	Dynavax Technologies Corporation	Complexes of a short cpg-containing oligonucleotide bound to the surface of a solid phase microcarrier and methods for use thereof
ES2314099T3 (es) *	2001-08-17	2009-03-16	Coley Pharmaceutical Gmbh	Oligonucleotidos inmunoestimulantes con motivos combinados con actividad mejorada.
AU2003219383B2 (en) *	2002-04-22	2010-08-26	Bioniche Life Sciences Inc.	Oligonucleotide compositions and their use for the modulation of immune responses
EP1551376A4 (en)	2002-08-12	2010-10-06	Dynavax Tech Corp	IMMUNOMODULATORY COMPOSITIONS, PREPARATION METHOD AND USER METHOD THEREFOR
ATE544772T1 (de) *	2002-12-23	2012-02-15	Dynavax Tech Corp	Immunstimulierende sequenz-oligonukleotide und verwendungsverfahren dafür
CA2669137A1 (en) *	2006-11-09	2008-06-19	Dynavax Technologies Corporation	Long term disease modification using immunostimulatory oligonucleotides

2003
- 2003-12-18 AT AT08013086T patent/ATE544772T1/de active
- 2003-12-18 DK DK03814325T patent/DK1575977T3/da active
- 2003-12-18 CA CA2511475A patent/CA2511475C/en not_active Expired - Lifetime
- 2003-12-18 DE DE60329223T patent/DE60329223D1/de not_active Expired - Lifetime
- 2003-12-18 KR KR1020127025824A patent/KR20120128729A/ko not_active Ceased
- 2003-12-18 AU AU2003297483A patent/AU2003297483B2/en not_active Expired
- 2003-12-18 KR KR1020127008544A patent/KR101309501B1/ko not_active Expired - Lifetime
- 2003-12-18 DK DK08013086.7T patent/DK1992635T3/da active
- 2003-12-18 CN CNB2003801073014A patent/CN100546998C/zh not_active Expired - Lifetime
- 2003-12-18 NZ NZ541027A patent/NZ541027A/en not_active IP Right Cessation
- 2003-12-18 ES ES03814325T patent/ES2328807T3/es not_active Expired - Lifetime
- 2003-12-18 PT PT08013086T patent/PT1992635E/pt unknown
- 2003-12-18 US US10/741,720 patent/US7745606B2/en not_active Expired - Lifetime
- 2003-12-18 ES ES08013086T patent/ES2381309T3/es not_active Expired - Lifetime
- 2003-12-18 AT AT03814325T patent/ATE442376T1/de active
- 2003-12-18 EP EP08013086A patent/EP1992635B1/en not_active Expired - Lifetime
- 2003-12-18 SG SG2011035342A patent/SG2011035342A/en unknown
- 2003-12-18 CN CN2009101704063A patent/CN101693890B/zh not_active Expired - Lifetime
- 2003-12-18 EP EP03814325A patent/EP1575977B1/en not_active Expired - Lifetime
- 2003-12-18 SI SI200331695T patent/SI1575977T1/sl unknown
- 2003-12-18 JP JP2005510051A patent/JP5102959B2/ja not_active Expired - Lifetime
- 2003-12-18 WO PCT/US2003/041001 patent/WO2004058179A2/en not_active Ceased
- 2003-12-18 PT PT03814325T patent/PT1575977E/pt unknown
- 2003-12-18 SG SG2007045727A patent/SG173219A1/en unknown
- 2003-12-18 KR KR1020057011912A patent/KR101178816B1/ko not_active Expired - Lifetime
2009
- 2009-11-25 CY CY20091101221T patent/CY1109642T1/el unknown
2011
- 2011-12-16 JP JP2011276052A patent/JP2012070757A/ja active Pending
2012
- 2012-04-25 CY CY20121100394T patent/CY1112704T1/el unknown

Also Published As

Publication number	Publication date
EP1992635A1 (en)	2008-11-19
CY1109642T1 (el)	2014-08-13
CN101693890A (zh)	2010-04-14
EP1575977A2 (en)	2005-09-21
KR20120128729A (ko)	2012-11-27
CA2511475A1 (en)	2004-07-15
DK1575977T3 (da)	2009-11-09
SI1575977T1 (sl)	2010-01-29
KR101309501B1 (ko)	2013-09-24
SG2011035342A (en)	2016-12-29
CA2511475C (en)	2013-11-19
KR20120046326A (ko)	2012-05-09
ATE442376T1 (de)	2009-09-15
EP1575977A4 (en)	2006-04-26
JP2012070757A (ja)	2012-04-12
JP2006512096A (ja)	2006-04-13
HK1125943A1 (en)	2009-08-21
EP1992635B1 (en)	2012-02-08
PT1575977E (pt)	2009-12-15
NZ541027A (en)	2008-04-30
ES2381309T3 (es)	2012-05-25
AU2003297483A1 (en)	2004-07-22
CY1112704T1 (el)	2016-02-10
SG173219A1 (en)	2011-08-29
JP5102959B2 (ja)	2012-12-19
EP1575977B1 (en)	2009-09-09
KR101178816B1 (ko)	2012-09-07
AU2003297483B2 (en)	2010-11-18
KR20050089983A (ko)	2005-09-09
CN100546998C (zh)	2009-10-07
PT1992635E (pt)	2012-03-20
ES2328807T3 (es)	2009-11-18
US7745606B2 (en)	2010-06-29
CN1745089A (zh)	2006-03-08
ATE544772T1 (de)	2012-02-15
WO2004058179A2 (en)	2004-07-15
CN101693890B (zh)	2012-09-05
US20060058254A1 (en)	2006-03-16
DE60329223D1 (de)	2009-10-22
WO2004058179A3 (en)	2004-11-11

Publication	Publication Date	Title
DK1575977T3 (da)	2009-11-09	Oligonukleotider med Immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse
DE60142410D1 (de)	2010-07-29	Immunomodulatorische polynukleotide und verfahren zur deren verwendung
DK1545597T3 (da)	2011-01-31	Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
EP2423335A3 (en)	2012-08-08	Chimeric immunomodulatory compounds and methods of using the same
DK1475721T3 (da)	2013-05-27	Brugerautentificeringsfremgangsmåde og brugerautentificeringssystem
DK1411789T3 (da)	2006-05-22	Fremgangsmåde og anordning til forögelse af hårvolumen
DK1436999T3 (da)	2011-07-18	Generering af scramblingkode med specifik brugerudstyrsidentifikation til den delte højhastighedskontrolkanal
DE60336209D1 (de)	2011-04-14	Heizvorrichtung, fixiervorrichtung und bilderzeugungsvorrichtung
AU2003279814A8 (en)	2004-04-23	Fluid-handling apparatus and methods
WO2004058159A3 (en)	2005-12-22	Branched immunomodulatory compounds and methods of using the same
IS7369A (is)	2004-07-23	Aðferð og tæki til örflögunýmyndunar
NO20053771D0 (no)	2005-08-08	Ringromsfluider og fremgangsmater for plassering av de samme
DK1554250T3 (da)	2007-12-17	Hidtil ukendt lactamer og anvendelser deraf
DE60125429D1 (de)	2007-02-01	Zolpidem hemitartrat solvat
NO20035562D0 (no)	2003-12-12	System og fremgangsmåte for forenklet initiering av konferanser
DK1523243T3 (da)	2007-05-21	Mælkeproteinisolat og metode til fremstilling af samme
DK1455794T3 (da)	2011-03-14	CIC-2 kanalåbner til behandling af mave- eller tarmsår
DK1589973T4 (da)	2013-04-08	Formulering og fremgangsmåder til behandling af thrombocytæmi
EP1351495A4 (en)	2007-07-25	gradation correcting
DE60207802D1 (de)	2006-01-12	CDMA-Empfänger und Kanalschätzungsverfahren
DK1662867T3 (da)	2014-07-21	Insekticid-forbindelser og fremgangsmåder til valg deraf
ITRM20010331A0 (it)	2001-06-11	Apparato e metodo di perforazione.
NO20053903D0 (no)	2005-08-22	Nukleotidlipidesterderivater.
NO20040932L (no)	2004-04-01	Egnet stigerorsstrekkapparat, metode og system
ITMI20030178A1 (it)	2003-08-05	Apparecchiatura e procedimento di fissaggio/ritenuta